Please ensure Javascript is enabled for purposes of website accessibility

Should You Sell Biogen Stock?

By Prosper Junior Bakiny – Jun 10, 2020 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With the biotech facing two issues each that could result in major headwinds, a Bernstein analyst has downgraded its stock.

Biogen (BIIB -1.01%) has taken its shareholders on a roller-coaster ride over the past year or so, and more potential trouble is on the horizon for the biotech. Given that, now may be a good time for shareholders to consider jumping ship -- at least, so says Bernstein analyst Aaron Gal.

Patent risks and drug approval long shots

Gal believes that Biogen has a 70% chance of losing a patent lawsuit filed by Mylan (MYL) over the multiple sclerosis drug Tecfidera. Tecfidera is currently Biogen's best-selling product. During the first quarter, its sales accounted for roughly $1.1 billion of its $3.5 billion in total revenue. If the patent in question is invalidated, Tecfidera would face generic competition immediately, rather than in 2028, which could take a major bite out of Biogen's finances. 

Bear standing in front of  a red price chart.

Image Source: Getty Images.

Further, there's the controversy surrounding aducanumab, a potential treatment for Alzheimer's disease. Biogen discontinued the development of the drug candidate in March 2019, revealing that it had failed to prove effective against the symptoms of Alzheimer's in a phase 3 clinical trial. However, the biotech changed its tune on aducanumab in October after analysis of a larger data set revealed that Alzheimer's patients treated with the drug experienced "significant benefits on measures of cognition and function."

The company said at the time that it would submit a Biologic License Application for the drug "in early 2020," but halfway through the year, Biogen has yet to do so.

The combination of those issues prompted Gal to downgrade the company's stock from outperform (buy) to market perform (neutral). The analyst also cut Biogen's stock price target from $360 to $297, which is less than $1 above where it's trading Wednesday afternoon.

Should investors heed Aaron Gal's advice on Biogen? 

I think so -- or at the very least, I believe Biogen is a high-risk, high-reward play at the moment. Sure, the company could fend off the patent challenge to Tecfidera, and it could also earn regulatory approval for aducanumab. If both of those things happen, Biogen's stock will skyrocket. But if even one of those situations goes the wrong way for the company, its shares will fall off a cliff. How likely is it, then, that Biogen will be successful on both fronts? Not likely, in my view, which is why I think this biotech stock is too risky for most investors. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$264.30 (-1.01%) $-2.70
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.